VEGFB and fibrosis: Pathological hypertrophy is characterized by functional decline, cardiac fibrosis, and inflammation.45 Here, aged mice after AAV9-Vegfb-treatment displayed improved diastolic function and heart rate variability, accompanied by reduced fibrosis and unaffected inflammatory marker expression.